Poll: Lipoprotein(a): What is Your Clinical Practice?

Elevated Lipoprotein(a) [Lp(a)] is one of the leading inherited dyslipidemias associated with premature atherosclerotic cardiovascular disease (ASCVD) including coronary artery disease or ischemic stroke.1,2 High plasma Lp(a) concentrations are also associated with aortic stenosis.3


  1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol 2019;73:3168-3209.
  2. Authors/Task Force Members, ESC Committee for Practice Guidelines, ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205.
  3. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374-92.

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Prevention, Valvular Heart Disease, Atherosclerotic Disease (CAD/PAD), Advanced Lipid Testing, Lipid Metabolism

Keywords: Primary Prevention, Lipoprotein(a), Dyslipidemias, Plaque, Atherosclerotic, Coronary Artery Disease, Stroke, Aortic Valve Stenosis

< Back to Listings